WO1997026900A1 - Gastro-resistant pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of erectile dysfunctions - Google Patents
Gastro-resistant pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of erectile dysfunctions Download PDFInfo
- Publication number
- WO1997026900A1 WO1997026900A1 PCT/EP1997/000331 EP9700331W WO9726900A1 WO 1997026900 A1 WO1997026900 A1 WO 1997026900A1 EP 9700331 W EP9700331 W EP 9700331W WO 9726900 A1 WO9726900 A1 WO 9726900A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- colostrum
- treatment
- gastro
- pharmaceutical formulations
- erectile dysfunctions
- Prior art date
Links
- 210000003022 colostrum Anatomy 0.000 title claims abstract description 27
- 235000021277 colostrum Nutrition 0.000 title claims abstract description 27
- 201000001881 impotence Diseases 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims abstract description 11
- 208000010228 Erectile Dysfunction Diseases 0.000 title claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 241000283073 Equus caballus Species 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000011049 pearl Substances 0.000 claims description 2
- 235000008476 powdered milk Nutrition 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- -1 phentolamine Chemical compound 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 206010056303 Painful erection Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 150000003022 phthalic acids Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
Definitions
- the present invention relates to gastro-resistant pharmaceutical formulations containing animal colostrum for the treatment of erectile dysfunctions, and the use of colostrum for the treatment of erectile dysfunctions.
- Impotence is a dysfunction consisting in the inability to attain or sustain the erection of penis.
- Etiological factors of impotence can be either physical (androgen low levels; diseases of the genito ⁇ urinary tract; diabetes mellitus; drug dependency and alcoholism; local or neurogenic vascular disturbances; use of antihypertensives, amphetamines, tranquillizers and sedatives), or psychic (emotional and psychotic disturbances, stress, anxiety, depression).
- the treatment can be surgical (penile prosthesis are implanted in the penis or in the testicular bag to electrically stimulate erigentes nerves) or pharmacological (injection of vasodilators, such as papaverine, or ⁇ -blockers, such as phentolamine, in the cavernous bodies; topical administration of vasodilators, such as inoxidil).
- penile prosthesis are implanted in the penis or in the testicular bag to electrically stimulate erigentes nerves
- pharmacological injection of vasodilators, such as papaverine, or ⁇ -blockers, such as phentolamine, in the cavernous bodies
- topical administration of vasodilators such as inoxidil
- the patient is not particularly in favour of the surgical approach; on the other hand, the pharmacological treatment also is not particularly attractive, in view of both the site of the injection (which is effected by the physician or by the patient himself) and the disagreeable side-effects (risk of prolonged, painful erection or overdose).
- the present invention aims at overcoming the above cited problems, by the use of gastro-resistant pharmaceutical formulations containing equine, bovine or anyhow animal, but preferably equine, colostrum, to induce erection.
- the present invention further relates to the use of equine, bovine or anyhow animal, but preferably equine, colostrum, in the treatment of erectile dysfunctions.
- the gastro-resistant pharmaceutical formulations of invention contain powder or liquid colostrum in amounts of 10 mg to 5 g per unitary dose.
- gastro-resistant tablets or pearls of invention are prepared according to the conventional pharmaceutical techniques for the preparation of gastro- resistant formulations, for example an enteric coating can be applied to a colostrum core by means of fluidized bed coating or pan coating techniques.
- the enteric coating is used to protect colostrum against the gastric acid environment, such a coating can consist of copoly erized methacrylic acid/methacrylic acid methyl esters, such as those known under the names
- Eudragit R (commercialized by Rohm Pharma), polymers such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, water-based polymer dispersions, such as Eudragit R (by Rohm Pharma),
- the enteric coating can optionally contain plasticizers such as triacetin, cetanol, citric and phthalic acids esters.
- the formulations of the invention can optionally contain other active ingredients known to have a beneficial effect on the condition to treat, particularly vegetable extracts.
- the formulations of invention will be administered to the patient suffering from erectile dysfunctions at night, before the sexual intercourse.
- the formulations can contain colostrum mixed with milk.
- Example 1 One enteric-coated tablet contains:
- the enteric coating solution is applied on the colostrum core by fluidized bed coating.
- One enteric-coated tablet contains:
- the enteric coating solution is applied on the colostrum core by fluidized bed coating.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU14450/97A AU1445097A (en) | 1996-01-26 | 1997-01-24 | Gastro-resistant pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of erectile dysfunctions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI96A000133 | 1996-01-26 | ||
| IT96MI000133A IT1282953B1 (it) | 1996-01-26 | 1996-01-26 | Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento di disfunzioni erettili |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997026900A1 true WO1997026900A1 (en) | 1997-07-31 |
Family
ID=11373032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1997/000331 WO1997026900A1 (en) | 1996-01-26 | 1997-01-24 | Gastro-resistant pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of erectile dysfunctions |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU1445097A (enrdf_load_stackoverflow) |
| IT (1) | IT1282953B1 (enrdf_load_stackoverflow) |
| WO (1) | WO1997026900A1 (enrdf_load_stackoverflow) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0046909A2 (en) * | 1980-08-29 | 1982-03-10 | Sendai Institute Of Microbiology | Pharmaceutical composition |
| WO1994016675A1 (en) * | 1993-01-26 | 1994-08-04 | Horse Vitality Ltd. | Pharmaceutical and dermocosmetic compositions containing equine colostrum |
-
1996
- 1996-01-26 IT IT96MI000133A patent/IT1282953B1/it active IP Right Grant
-
1997
- 1997-01-24 WO PCT/EP1997/000331 patent/WO1997026900A1/en active Application Filing
- 1997-01-24 AU AU14450/97A patent/AU1445097A/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0046909A2 (en) * | 1980-08-29 | 1982-03-10 | Sendai Institute Of Microbiology | Pharmaceutical composition |
| WO1994016675A1 (en) * | 1993-01-26 | 1994-08-04 | Horse Vitality Ltd. | Pharmaceutical and dermocosmetic compositions containing equine colostrum |
Non-Patent Citations (1)
| Title |
|---|
| Dialog Information Services, File 155, MEDLINE, Dialog accession no. 02818554, Doichev S et al: "Estrus induction in sheep injected with colostrum at different phases of the sexual cycle"; & Vet Med Nauki (BULGARIA) 1979, 16 (3) P40-4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1282953B1 (it) | 1998-04-02 |
| AU1445097A (en) | 1997-08-20 |
| ITMI960133A0 (enrdf_load_stackoverflow) | 1996-01-26 |
| ITMI960133A1 (it) | 1997-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69720985T3 (de) | Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung | |
| AU638414B2 (en) | Composition for the treatment of erectile dysfunction | |
| KR100280099B1 (ko) | 방출 개시 제어 및 방출 속도 제어형 제제 | |
| Porst | Transurethral alprostadil with MUSETM (medicated urethral system for erection) vs intracavernous alprostadil—a comparative study in 103 patients with erectile dysfunction | |
| CA2169071C (en) | Methods for modulating the human sexual response | |
| JP4531301B2 (ja) | ヒトの性的応答を調節するための方法及び製剤 | |
| US5792476A (en) | Sustained release glucocorticoid pharmaceutical composition | |
| US7084116B2 (en) | Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators | |
| CN107106873A (zh) | 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗 | |
| WO1995011024A1 (en) | Picosulphate dosage form | |
| WO2019082128A1 (en) | DELAYED-RELEASE RELEASE TABLETS AND METHODS OF USE | |
| NZ506020A (en) | Use of pharmaceutical combinations containing tramadol and an antiemetic | |
| US6890547B1 (en) | Glycyrrhizin preparations for transmucosal absorption | |
| CA3148226A1 (en) | Articles and methods for administration of therapeutic agents | |
| Lund-Olesen et al. | Intra-articular orgotein therapy in osteoarthritis of the knee. A double-blind, placebo-controlled trial | |
| WO1997026900A1 (en) | Gastro-resistant pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of erectile dysfunctions | |
| JP4370054B2 (ja) | 腸粘膜傷害の予防及び治療剤 | |
| KR20080105857A (ko) | 치질환 및 기타 항문 직장 질환 치료 활성을 가지는조성물과 이의 제조 방법 및 이를 이용한 치질환 치료제 | |
| AU696815C (en) | Methods for modulating the human sexual response | |
| US6927239B1 (en) | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses | |
| JPH01268640A (ja) | 生理機能活性剤 | |
| JP2023539391A (ja) | セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用 | |
| JPH0769908A (ja) | 脳機能改善剤 | |
| WO1997026898A1 (en) | Gastro-resistant pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of insomnia | |
| RU2000108551A (ru) | Фармацевтическая композиция для лечения дисменореи и преждевременных родов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97526556 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |